ECOR electroCore

electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th

electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th

ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November 4, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.

Thursday, November 4, 2021, 4:30pm Eastern Time

Domestic: 877-269-7756

International: 201-689-7817

Conference ID: 13722407

Webcast:

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit .



Investors:
Rich Cockrell
CG Capital
404-736-3838
 tal

or

Media Contact:
Jackie Dorsky
electroCore
908-313-6331
EN
21/10/2021

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Participate at the Canaccord Genuity MedTech, Diagnosti...

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel. Management will host one-on-one meetings throughout the day. Investors who wish to request a...

November 10, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Third Quarter 2025 Financial Results

electroCore Announces Third Quarter 2025 Financial Results Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities (“Total Cash”) of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for t...

November 5, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Announce Third Quarter September 30, 2025 Financial Res...

electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025 ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, Novemb...

October 23, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(...

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employment. The RSUs were...

October 3, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctiv...

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). “The CDC reports approximately 2.5 mil...

September 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch